MX2021013364A - Composiciones utiles para el tratamiento de la enfermedad de pompe. - Google Patents
Composiciones utiles para el tratamiento de la enfermedad de pompe.Info
- Publication number
- MX2021013364A MX2021013364A MX2021013364A MX2021013364A MX2021013364A MX 2021013364 A MX2021013364 A MX 2021013364A MX 2021013364 A MX2021013364 A MX 2021013364A MX 2021013364 A MX2021013364 A MX 2021013364A MX 2021013364 A MX2021013364 A MX 2021013364A
- Authority
- MX
- Mexico
- Prior art keywords
- raav
- pompe disease
- treatment
- useful compositions
- useful
- Prior art date
Links
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 title abstract 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 title abstract 3
- 201000004502 glycogen storage disease II Diseases 0.000 title abstract 3
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 2
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 102000045921 human GAA Human genes 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840911P | 2019-04-30 | 2019-04-30 | |
| US201962913401P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/030493 WO2020223362A1 (en) | 2019-04-30 | 2020-04-29 | Compositions useful for treatment of pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013364A true MX2021013364A (es) | 2022-01-26 |
Family
ID=73029176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013364A MX2021013364A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
| MX2021013365A MX2021013365A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013365A MX2021013365A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220193207A1 (https=) |
| EP (2) | EP3980548A4 (https=) |
| JP (2) | JP2022530824A (https=) |
| KR (2) | KR20220004696A (https=) |
| CN (2) | CN114127275A (https=) |
| AU (2) | AU2020266829A1 (https=) |
| BR (2) | BR112021021792A2 (https=) |
| CA (2) | CA3134523A1 (https=) |
| CL (2) | CL2021002754A1 (https=) |
| CO (2) | CO2021016198A2 (https=) |
| IL (2) | IL287522A (https=) |
| MX (2) | MX2021013364A (https=) |
| PH (2) | PH12021552638A1 (https=) |
| SG (2) | SG11202111400TA (https=) |
| TW (1) | TW202100541A (https=) |
| WO (2) | WO2020223362A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3635009T3 (fi) | 2017-06-07 | 2026-04-07 | Regeneron Pharma | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| CN115087458A (zh) * | 2019-10-10 | 2022-09-20 | 阿米库斯治疗学公司 | 变体igf2构建体 |
| KR20230010255A (ko) * | 2020-05-14 | 2023-01-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 폼페병의 치료에 유용한 조성물 |
| US20230220069A1 (en) | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| EP4430201A4 (en) * | 2021-11-12 | 2026-04-08 | Univ Pennsylvania | Gene therapy for the treatment of mucopolysaccharidosis IIIA |
| NL2031676B1 (en) * | 2022-04-22 | 2023-11-07 | Univ Erasmus Med Ct Rotterdam | Gene therapy for Pompe Disease |
| WO2024003687A1 (en) * | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
| WO2024151982A1 (en) * | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
| CN116693633B (zh) * | 2023-02-21 | 2023-12-22 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2025171163A1 (en) * | 2024-02-06 | 2025-08-14 | Duke University | Compositions for and methods of treating lysosomal storage diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE521701T1 (de) * | 2003-01-22 | 2011-09-15 | Univ Duke | Verbesserte konstrukte zur expression lysosomaler polypeptide |
| CN1922313B (zh) * | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
| US20090117091A1 (en) * | 2006-11-13 | 2009-05-07 | Lebowitz Jonathan | Methods for treating pompe disease |
| EP2623599B1 (en) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| HRP20170698T1 (hr) * | 2008-05-07 | 2017-09-22 | Biomarin Pharmaceutical Inc. | Lizosomski usmjereni peptidi i njihove uporabe |
| US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
| JP5755569B2 (ja) * | 2009-02-25 | 2015-07-29 | セファイド | 肺癌を検出する方法 |
| EP2475376B1 (en) * | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| US9279007B2 (en) | 2010-11-22 | 2016-03-08 | Amicus Therapeutics, Inc. | Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
| WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| LT2714752T (lt) * | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| WO2013013019A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Lysosomal polypeptides, methods of making and using |
| CN107405411A (zh) * | 2014-05-01 | 2017-11-28 | 华盛顿大学 | 使用腺病毒载体的体内基因改造 |
| KR102423442B1 (ko) * | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| IL325155A (en) * | 2016-03-30 | 2026-02-01 | Amicus Therapeutics Inc | Formulations containing recombinant acid alpha-glucosidase |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293260A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| MX2019002842A (es) * | 2016-09-12 | 2019-08-29 | Genethon | Variantes de alfa-glucosidasa acida y usos de las mismas. |
| CA3057899A1 (en) * | 2017-03-27 | 2018-10-04 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
| JP2018198611A (ja) * | 2018-08-03 | 2018-12-20 | ウニベルシダッド アウトノマ デ バルセロナ | 脂肪組織に形質導入するのに有用なアデノ随伴ウイルスベクター |
-
2020
- 2020-04-29 CN CN202080048355.1A patent/CN114127275A/zh active Pending
- 2020-04-29 TW TW109114314A patent/TW202100541A/zh unknown
- 2020-04-29 JP JP2021564730A patent/JP2022530824A/ja active Pending
- 2020-04-29 WO PCT/US2020/030493 patent/WO2020223362A1/en not_active Ceased
- 2020-04-29 MX MX2021013364A patent/MX2021013364A/es unknown
- 2020-04-29 PH PH1/2021/552638A patent/PH12021552638A1/en unknown
- 2020-04-29 SG SG11202111400TA patent/SG11202111400TA/en unknown
- 2020-04-29 WO PCT/US2020/030484 patent/WO2020223356A1/en not_active Ceased
- 2020-04-29 BR BR112021021792A patent/BR112021021792A2/pt unknown
- 2020-04-29 KR KR1020217038231A patent/KR20220004696A/ko not_active Withdrawn
- 2020-04-29 US US17/606,410 patent/US20220193207A1/en not_active Abandoned
- 2020-04-29 CN CN202080049015.0A patent/CN114072515A/zh active Pending
- 2020-04-29 EP EP20798851.0A patent/EP3980548A4/en not_active Withdrawn
- 2020-04-29 SG SG11202111380VA patent/SG11202111380VA/en unknown
- 2020-04-29 JP JP2021565001A patent/JP7585233B2/ja active Active
- 2020-04-29 CA CA3134523A patent/CA3134523A1/en active Pending
- 2020-04-29 EP EP20799541.6A patent/EP3963063A4/en not_active Withdrawn
- 2020-04-29 PH PH1/2021/552637A patent/PH12021552637A1/en unknown
- 2020-04-29 US US17/606,414 patent/US20220193261A1/en active Pending
- 2020-04-29 AU AU2020266829A patent/AU2020266829A1/en not_active Abandoned
- 2020-04-29 KR KR1020217038223A patent/KR20220008280A/ko not_active Withdrawn
- 2020-04-29 AU AU2020266552A patent/AU2020266552A1/en not_active Abandoned
- 2020-04-29 CA CA3134485A patent/CA3134485A1/en active Pending
- 2020-04-29 BR BR112021021720A patent/BR112021021720A2/pt unknown
- 2020-04-29 MX MX2021013365A patent/MX2021013365A/es unknown
-
2021
- 2021-10-20 CL CL2021002754A patent/CL2021002754A1/es unknown
- 2021-10-20 CL CL2021002755A patent/CL2021002755A1/es unknown
- 2021-10-24 IL IL287522A patent/IL287522A/en unknown
- 2021-10-24 IL IL287523A patent/IL287523A/en unknown
- 2021-11-29 CO CONC2021/0016198A patent/CO2021016198A2/es unknown
- 2021-11-29 CO CONC2021/0016200A patent/CO2021016200A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013364A (es) | Composiciones utiles para el tratamiento de la enfermedad de pompe. | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
| EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
| PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
| BR112019023303A2 (pt) | Terapia de gene para lipofuscinoses ceroides neuronais | |
| AR119869A1 (es) | Proteína vp1 modificada aislada de la cápside del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en la misma | |
| EA202091352A1 (ru) | Генотерапия мукополисахаридоза iiib | |
| CO2021011040A2 (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio en adultos asociada a grn | |
| CO2022017959A2 (es) | Composiciones para la reducción específica de la expresión transgénica en drg. | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| MX2022004352A (es) | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c. | |
| García‐Olloqui et al. | Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors | |
| ECSP24013002A (es) | Proteína vp1 de la cápsida aav9 modificada aislada | |
| AR122260A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| EA202192973A1 (ru) | Композиции, полезные для лечения болезни помпе | |
| Chen et al. | Recent advances in cardiac gene therapy strategies targeting advanced heart failure | |
| PE20241345A1 (es) | Proteina vp1 modificada y aislada de la capside del virus adenoasociado del serotipo 5 (aav5), capside y vector basados en esta | |
| AR123725A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad de fabry | |
| RU2022123359A (ru) | Новые капсидные белки аденоассоциированного вируса | |
| AR120249A1 (es) | Vectores virales adeno-asociados para el tratamiento de la enfermedad de niemann-pick tipo c | |
| PY2272100A (es) | Método de obtención de una cápside de virus adeno-asociado modificada | |
| AR122261A1 (es) | Composiciones y métodos para el tratamiento de taupatía | |
| AR122251A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de krabbe | |
| EA201992032A1 (ru) | Композиции, пригодные при лечении спинальной мышечной атрофии |